z-logo
open-access-imgOpen Access
Beta‐lapachone inhibits pathological retinal neovascularization in oxygen‐induced retinopathy via regulation of HIF ‐1α
Author(s) -
Park Sung Wook,
Kim Jin Hyoung,
Kim KoEun,
Jeong Moon Hee,
Park Hyunsung,
Park Bongju,
Suh YoungGer,
Park Woo Jin,
Kim Jeong Hun
Publication year - 2014
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.12235
Subject(s) - neovascularization , retinal , retinopathy , beta (programming language) , pathological , ophthalmology , medicine , chemistry , biology , cancer research , pathology , angiogenesis , endocrinology , computer science , diabetes mellitus , programming language
Retinal neovascularization in retinopathy of prematurity ( ROP ) is the most common cause of blindness for children. Despite evidence that hypoxia inducible factor ( HIF )‐1α ‐ VEGF axis is associated with the pathogenesis of ROP , the inhibitors of HIF ‐1α have not been established as a therapeutic target in the control of ROP pathophysiology. We investigated the hypothesis that degradation of HIF ‐1α as a master regulator of angiogenesis in hypoxic condition, using β‐lapachone, would confer protection against hypoxia‐induced retinopathy without affecting physiological vascular development in mice with oxygen‐induced retinopathy ( OIR ), an animal model of ROP . The effects of β‐lapachone were examined after intraocular injection in mice with OIR . Intraocular administration of β‐lapachone resulted in significant reduction in hypoxia‐induced retinal neovascularization without retinal toxicity or perturbation of developmental retinal angiogenesis. Our results demonstrate that HIF ‐1α–mediated VEGF expression in OIR is associated with pathological neovascularization, not physiological angiogenesis. Thus, strategies blocking HIF ‐1α in the developing eye in the pathological hypoxia could serve as a novel therapeutic target for ROP .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here